Pasteur
-
Sanofi Pasteur acquires exclusive, worldwide license for acne vaccine and treatment
Pre-clinical vaccine was developed by researchers at the University of California, San Diego.
Pasteur | 21 September 2011
-
Sanofi Pasteur donates vaccine strain used for polio eradication to WHO
Vaccine strain used in the production of oral polio vaccines against type 3 poliovirus.
Pasteur | 20 September 2011
-
Sanofi Pasteur’s typhoid vaccine granted prequalification by WHO
Designation will facilitate global access to vaccine for the prevention of typhoid fever in the most vulnerable populations around the world.
Pasteur | 23 June 2011
-
Sanofi Pasteur launches 5-in-1 combination vaccine in China
New vaccine Pentaxim reduces infant shots from twelve to four.
Pasteur | 11 May 2011
-
Institut Pasteur Korea and NITD Singapore Collaborate on Tuberculosis Drug Discovery
Institut Pasteur Korea (IPK) and Novartis Institute for Tropical Diseases (NITD), Singapore, have entered into a Services Frame Agreement for the identification of safe and effective new therapies for Tuberculosis infected individuals. This part…
Pasteur | 23 December 2009
-
Institut Pasteur Korea to Screen Pfizer Compound Library in Collaboration with DNDi
Institut Pasteur Korea and the Drugs for Neglected Diseases Initiative (DNDi) have entered into a collaborative agreement, centered on the use of Pfizer’s compound library. This is for the identification and development of safe, effective and affor…
Pasteur | 16 December 2009
-
Sanofi Pasteur Expands Dengue Vaccine Clinical Program in South East Asia
Sanofi Pasteur has announced the start of clinical studies of its investigational tetravalent dengue vaccine in Singapore and Vietnam. With these studies, the company is expanding its global dengue vaccine clinical study program in Asia where trials …
Pasteur | 25 June 2009
-
Sanofi Pasteur Lands US$190 Million Order from the US Government
Sanofi Pasteur has received the first of what is expected to be a series of orders from the US Department of Health and Human Services (HHS) to commence production of an influenza A(H1N1) vaccine. This order from HHS was issued pursuant to an exis…
Pasteur | 29 May 2009
-
High-dose influenza vaccine shows increased immune response among adults
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that an investigational high-dose influenza vaccine demonstrated increased immune responses among adults 65 years of age and older compared with the standard influenza vaccine. …
Pasteur | 04 November 2008
-
Sanofi Pasteur inaugurates high tech vaccine production facility
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has announced today the inauguration of a high-tech vaccine production facility in France to respond to soaring demand worldwide. This new 100 million euros ($159 million) facility lo…
Pasteur | 08 July 2008
